Retirement plan advisors can now access Nestimate’s Target-Date Fund IQ Analysis through PGIM, equipping fiduciaries with a plan-centric framework to evaluate Target Date Funds and lifetime income solutions Nestimate, the innovative investment due diligence platform, has announced that its Target-Date Fund IQ Analysis tool is now available through PGIM, giving retirement plan advisors access to an objective framework for evaluating target-date funds and lifetime income solutions. Through this collaboration, retirement plan advisors can reach out to their PGIM Defined Contribution (DC) Solutions representative to run Nestimate’s reporting, enabling them to work directly with their plan s
Press Releases
Delayed 3mFastest customizable press release feed in the world.
Signed out · 3-min delay · Sign up for real-time
- Nestimate Expands Access to Objective Target-Date Fund Evaluation Tool through Collaboration with PGIM
- High Roller Technologies Names Michael D. Franz as ROLR™ Prediction Challenge Season Champion
Multiple winners receive cash prizes during eight-week competition, with Season Champion earning $75,000 top prize LAS VEGAS, Nevada, Aug. 26, 2026 (GLOBE NEWSWIRE) -- High Roller Technologies, Inc. ("High Roller" or the "Company") (NYSE:ROLR), a publicly traded online gaming and prediction markets company, today announced the winners of the ROLR™ Free-To-Trade Prediction Challenge, which concluded August 12, 2026 following an eight-week competition that introduced participants to the ROLR prediction markets brand ahead of its planned commercial launch. Michael D. Franz, who competed under the ROLR username m3t64, emerged as the competition's Season Champion, earning the $75,000 Season C
- Cre8 Enterprise Limited Reports Record Number of Customers Served for the First Half of 2026
Hong Kong, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Cre8 Enterprise Limited (NASDAQ:CRE) ("Cre8" or the "Company"), a Hong Kong-based integrated financial printing service provider, announced today that the number of customers it served and its project backlog each reached record levels as of June 30, 2026, primarily driven by a surge in regional capital markets activity. The number of customers reached a new record level of 550 as of June 30, 2026, an increase of 83, or 17.8%, from 467 as of December 31, 2025, an increase of 149, or 37.2%, from 401 as of December 31, 2024, and an increase of 142, or 34.8%, from 408 as of June 30, 2025. More specifically, number of times of IPO filing submissio
- Syntec Optics (NASDAQ: OPTX) Wins New Recurring Space Order as Space Economy Expands
ROCHESTER, NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Syntec Optics Holdings, Inc. (NASDAQ:OPTX), a leading provider of deep tech for the defense, space, AI data centers, and other vibrant end-markets, today announced a new order to build specialized high-tech waveguides for space satellites. After working on it for the past six months, Syntec is now ramping up to build and ship the product every week. Syntec is making advanced antenna feeds that let satellites talk using several different channels, all at the same time. Usually, satellites need a whole bunch of different antennas, but when you work with some of the best talent in the nation as a customer, it is all done in one. However
- Rail Vision Delivers Strong Commercial Momentum in First Half of 2026 with Revenue Exceeding $1 Million
Revenues for the first half of 2026 exceeded $1.0 million, compared to $237,000 in the first half of 2025 ShuntingYard technology integrated into Railserve’s commercially launched YardGUARD system; successful field testing completed with Israel Railways Ra’anana, Israel, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (NASDAQ:RVSN, FSE: C80)) ("Rail Vision" or the "Company"), an early commercialization stage technology company transforming railway safety through advanced AI-integrated sensing systems, today announced its financial results for the first half ended June 30, 2026. "The first half of 2026 marked a period of strong commercial momentum for Rail Vision," said David BenDavid
- Better, Coinbase Announce General Availability of First Token-backed, Conforming Mortgage to Expand Homeownership Access for a New Generation of Mortgage Borrowers
Coinbase One members will be eligible for a lender-funded closing cost credit of up to $10,000 – applicable to all of Better’s home-financing products, including standard mortgages, HELOCs, and refinancesBetter Mortgage (NASDAQ:BETR) and Coinbase (NASDAQ:COIN) today announced general availability for Better’s token-backed, conforming mortgage product. These first-of-its-kind mortgages will be originated and serviced by Better, powered by Coinbase, and designed in accordance with guidelines from Fannie Mae, making the first lien a standard, conforming mortgage.As part of this offering, if approved for a loan by Better, Coinbase One members will be eligible for a rebate equal to 1% of the mort
- Xeris Announces Details for XP-8121 Program Overview Webinar
Webinar to Highlight Unmet Needs in Hypothyroidism, Market Opportunity, and Planned Phase 3 Program for XP-8121 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism. The XP-8121 webinar will take place on Wednesday, September 9, 2026, at 10 a.m. ET and will feature a leading endocrinologist, alongside members of the Xeris program te
- BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid regression in a subset of patients - ATTR-CM has long been treated as a disease where progression can be slowed, but these findings raise the possibility that acoramidis may be capable of reversing progression and actively restoring heart health. TTR stabilization with acoramidis may allow the body's natural amyloid clearance mechanisms to outpace amyloid formation, thereby enabling cardiac remodeling and functional recovery - ASCEND-ATTR will determine whether long-term acoramid
- Eikon Therapeutics to Participate in Investor Conferences in September 2026
MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September: Event:12th Annual Cantor Global Healthcare Conference Location: New York, NYDate & Time: September 10, 2026 at 2:10 pm ETFormat: Fireside Chat Event: The Morgan Stanley 24th Annual Global Healthcare ConferenceLocation: New York, NYDate
- Abercrombie & Fitch Co. Reports Second Quarter Fiscal 2026 Results
Record second quarter net sales of $1.3 billion, up 5% to last year, 15th consecutive quarter of growthNet sales growth across regions with Americas up 5%, APAC up 19%, and EMEA up 2%Best-ever second quarter sales across brands, led by Abercrombie brands up 8%, with Hollister up 2%Operating margin of 20%, and earnings per diluted share of $4.17, both above outlook in excess of IEEPA tariff refund benefit of approximately $100 million on a pre-tax basis and $1.75 per diluted share; impact presented in table below$177 million in shares repurchased in the quarter; year-to-date share repurchases of $282 million totaling 7% of shares outstanding at beginning of the yearUpdates full-year outlook t
- Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF
- Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on September 9th at 1:30 p.m. ET. A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repli
- Brandywine Realty Trust Announces Expiration of Tender Offer for the 2029 Notes
PHILADELPHIA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Brandywine Realty Trust (NYSE:BDN) announced today the expiration of the previously announced cash tender offer (the "2029 Notes Tender Offer") by its operating partnership, Brandywine Operating Partnership, LP (the "Operating Partnership"), for up to $70,000,000 in aggregate principal amount (the "2029 Series Cap") of its outstanding 8.875% guaranteed notes due 2029 (the "2029 Notes"). The Operating Partnership previously announced that it had extended the 2029 Notes Tender Offer for the 2029 Notes. The 2029 Notes Tender Offer expired at 5:00 p.m., New York City time, on Tuesday, August 25, 2026 (the "2029 Notes Expiration Date") pursuant to
- APi Group Announces Participation in 2026 Jefferies Global Industrials Conference
APi Group Corporation (NYSE:APG) ("APi" or the "Company") today announced that its senior leadership team will be participating in a fireside chat at the 2026 Jefferies Global Industrials Conference on Wednesday, September 9 at 9:30 a.m. ET. A live webcast link and archived replay will be available in the "Events" area on the Investor Relations page of APi’s website at APi Group Investor Relations - Events. Interested parties should check the Company’s website for any schedule updates or time changes. About APi: APi Group is a global, market-leading business services company providing statutorily mandated and contracted services across its Safety Services and Specialty Services segmen
- Super Hi Reports Unaudited Financial Results for the Second Quarter of 2026
SINGAPORE, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Super Hi International Holding Ltd. (NASDAQ:HDL) ("Super Hi" or the "Company"), a leading Chinese cuisine restaurant brand operating Haidilao hot pot restaurants in the international markets, today announced its unaudited financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Highlights Revenue was US$218.8 million, representing an increase of 10.0% from US$198.9 million in the same period of 2025.In the second quarter of 2026, the Company opened 2 new Haidilao restaurants. The total number of Haidilao restaurants expanded from 127 as of March 31, 2026, to 129 as of June 30, 2026.Overall average table turnover rate1
- Dycom Announces Authorization of a New $150 Million Stock Repurchase Program
WEST PALM BEACH, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Dycom Industries, Inc. (NYSE:DY) today announced that its Board of Directors has authorized a new $150 million program to repurchase shares of Dycom’s outstanding common stock. Repurchases under the new program are authorized to be made over the next eighteen (18) months in open market purchases or privately-negotiated transactions, including pursuant to a Rule 10b5-1 plan. The exact timing and amount of repurchases, if any, will depend on market conditions and other factors. The repurchase program does not obligate Dycom to acquire any particular amount of common stock, and may be suspended or discontinued at any time. The new progr
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Definium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET Moderator: Paul Matteis, Head of Therapeutics Research Focus: Discussion of Definium’s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety
- Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
DUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Issuer also intends to grant the initial purchasers of the notes the right to purchase, exercisable within a 13-day period from, and including the initial issue date of the notes,
- LightInTheBox Reports Second Quarter 2026 Financial Results
SINGAPORE, Aug. 26, 2026 /PRNewswire/ -- LightInTheBox Holding Co., Ltd. (NYSE:LITB) ("LightInTheBox" or the "Company"), a global consumer lifestyle company, today announced its unaudited financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial HighlightsTotal Revenues were $56.8 million, a modest 4% decrease year over year, as the company optimized its product mix through phasing out long-tail products.Gross Profit was $37.6 million, compared with $38.8 million in the same quarter last year.Gross Margin was 66.1%, compared with 65.9% in the same quarter last year, which remained stable.Operating Expenses were $35.5 million, compared with $36.9 million in t
- Insmed to Present at September 2026 Investor Conferences
BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET.24th Annual Morgan Stanley Global Healthcare Conference in New York City on Monday, September 14, 2026, at 2:35 p.m. ET.These events will be webcasted live and can be accessed by visiting the investor relations section of the Company's website a